Skin Reactions to Immune Checkpoint Inhibitors.
Anti-CTLA-4
Dermatitis
Immune checkpoint inhibitors
Immunotherapy
Ipilimumab
Nivolumab Anti-PD-1
Pruritus
Rash
Journal
Advances in experimental medicine and biology
ISSN: 0065-2598
Titre abrégé: Adv Exp Med Biol
Pays: United States
ID NLM: 0121103
Informations de publication
Date de publication:
2021
2021
Historique:
entrez:
1
1
2022
pubmed:
2
1
2022
medline:
5
1
2022
Statut:
ppublish
Résumé
Due to the novelty of immune checkpoint inhibitors, their cutaneous adverse events (AEs) have only been recently characterized. This, along with the substantial rate of cutaneous reactions, has left many clinicians without sufficient familiarity to diagnose and treat cutaneous AEs. Pruritus and rash are among the top five immune-related AEs reported in clinical trials for this class of therapy. Incidence varies between 35 and 60% for cutaneous AEs among the seven FDA-approved drugs used as monotherapy or combination therapy. Although only 2% are reported as grade 3 or 4 events with monotherapy, the incidence can be as high as 6-9% for combination therapy and the impact on quality of life can be significant for these patients. Of ipilimumab patients, 43.5% have a cutaneous AE, and, at our institution, 20% of them had a dose interruption as a result. This means potentially 9% of patients have dose interruption of ipilimumab because of their cutaneous AEs. In the following chapter, we review the categories of these drugs, common cutaneous effects, their grading, and management options.
Identifiants
pubmed: 34972971
doi: 10.1007/978-3-030-79308-1_11
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Ipilimumab
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
319-330Informations de copyright
© 2021. The Author(s), under exclusive license to Springer Nature Switzerland AG.
Références
Naing, A., Hajjar, J., Gulley, J. L., Atkins, M. B., Ciliberto, G., Meric-Bernstam, F., & Hwu, P. (2020). Strategies for improving the management of immune-related adverse events. Journal for Immunotherapy of Cancer, 8(2), e001754.
doi: 10.1136/jitc-2020-001754
Villadolid, J., & Amin, A. (2015). Immune checkpoint inhibitors in clinical practice: Update on management of immune-related toxicities. Translational Lung Cancer Research, 4(5), 560–575.
pubmed: 26629425
pmcid: 4630514
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., et al. (2019). Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. The New England Journal of Medicine, 381(16), 1535–1546.
doi: 10.1056/NEJMoa1910836
Long, G. V., Atkinson, V., Cebon, J. S., et al. (2017). Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): An open-label, phase 1b trial. The Lancet Oncology, 18(9), 1202–1210.
doi: 10.1016/S1470-2045(17)30428-X
Sanlorenzo, M., Vujic, I., Daud, A., et al. (2015). Pembrolizumab cutaneous adverse events and their association with disease progression. JAMA Dermatology, 151(11), 1206–1212.
doi: 10.1001/jamadermatol.2015.1916
Teulings, H. E., Limpens, J., Jansen, S. N., et al. (2015). Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: A systematic review and meta-analysis. Journal of Clinical Oncology, 33(7), 773–781.
doi: 10.1200/JCO.2014.57.4756
Attia, P., Phan, G. Q., Maker, A. V., et al. (2005). Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. Journal of Clinical Oncology, 23(25), 6043–6053.
doi: 10.1200/JCO.2005.06.205
Sundaresan, S., Nguyen, K. T., Nelson, K. C., Ivan, D., & Patel, A. B. (2017). Erythema multiforme major in a patient with metastatic melanoma treated with nivolumab. Dermatology Online Journal, 23(9).
Kubicki, S. L., Welborn, M. E., & Patel, A. B. (2018). Toxic epidermal necrolysis during co-therapy with ipilimumab and nivolumab. Journal of Immunotherapy and Precision Oncology, 1(2), 78–81.
doi: 10.4103/JIPO.JIPO_7_18
Hodi, F. S., O’Day, S. J., McDermott, D. F., et al. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. The New England Journal of Medicine, 363, 711–23.5.
doi: 10.1056/NEJMoa1003466
Robert, C., Thomas, L., Bondarenko, I., et al. (2011). Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. The New England Journal of Medicine, 364, 2517–2526.
doi: 10.1056/NEJMoa1104621
Robert, C., Ribas, A., Wolchok, J. D., et al. (2014). Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial. Lancet, 384, 1109–17.7.
doi: 10.1016/S0140-6736(14)60958-2
Robert, C., Long, G. V., Brady, B., et al. (2015). Nivolumab in previously untreated melanoma without BRAF mutation. The New England Journal of Medicine, 372, 320–330.
doi: 10.1056/NEJMoa1412082
Weber, J. S., D’Angelo, S. P., Minor, D., et al. (2015). Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate037): A randomised, controlled, open label, phase 3 trial. The Lancet Oncology, 16, 375–384.
doi: 10.1016/S1470-2045(15)70076-8
Rizvi, N. A., Mazières, J., Planchard, D., et al. (2015). Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): A phase 2, single-arm trial. The Lancet Oncology, 16, 257–265.
doi: 10.1016/S1470-2045(15)70054-9
Garon, E. B., Rizvi, N. A., Hui, R., et al. (2015). Pembrolizumab for the treatment of non-small-cell lung cancer. The New England Journal of Medicine, 372, 2018–2028.
doi: 10.1056/NEJMoa1501824
Di Giacomo, A. M., Biagioli, M., & Maio, M. (2010). The emerging toxicity profiles of anti-CTLA-4 anti-bodies across clinical indications. Seminars in Oncology, 37(5), 499–507.
doi: 10.1053/j.seminoncol.2010.09.007
Fujii, T., Colen, R. R., Bilen, M. A., et al. (2018). Incidence of immune-related adverse events and its association with treatment outcomes: The MD Anderson Cancer Center experience. Investigational New Drugs, 36(4), 638–646.
doi: 10.1007/s10637-017-0534-0
Horvat, T. Z., Adel, N. G., Dang TO, et al. (2015). Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. Journal of Clinical Oncology, 33(28), 3193–3198.
doi: 10.1200/JCO.2015.60.8448
Coleman, E., Ko, C., Dai, F., Tomayko, M. M., Kluger, H., & Leventhal, J. S. (2019). Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management. Journal of the American Academy of Dermatology, 80(4), 990–997.
doi: 10.1016/j.jaad.2018.10.062
Karri, P. V., Tahseen, D., & Patel, A. B. (2020). Treatment of checkpoint inhibitor-induced vitiligo in a patient with metastatic renal cell cancer. Dermatitis. Published online December 1.
Daxini, A., Cronin, K., & Sreih, A. G. (2018). Vasculitis associated with immune checkpoint inhibitors-a systematic review. Clinical Rheumatology, 37(9), 2579–2584.
doi: 10.1007/s10067-018-4177-0
Cappelli, L. C., Shah, A. A., & Bingham, C. O. (2016). Cancer immunotherapy-induced rheumatic diseases emerge as new clinical entities. RMD Open, 2(2), e000321.
doi: 10.1136/rmdopen-2016-000321
Messer, A., Drozd, B., Glitza, I. C., Lu, H., & Patel, A. B. (2020). Dermatomyositis associated with nivolumab therapy for melanoma: A case report and review of the literature. Dermatology Online Journal, 26(8).
Lacouture, M. E., Wolchok, J. D., Yosipovitch, G., Kähler, K. C., Busam, K. J., & Hauschild, A. (2014). Ipilimumab in patients with cancer and the management of dermatologic adverse events. Journal of the American Academy of Dermatology, 71(1), 161–169.
doi: 10.1016/j.jaad.2014.02.035
Nayar, N., Briscoe, K., & Fernandez, P. P. (2016). Toxic epidermal necrolysis-like reaction with severe satellite cell necrosis associated with nivolumab in a patient with ipilimumab refractory meta-static melanoma. Journal of Immunotherapy, 39(3), 149–152.
doi: 10.1097/CJI.0000000000000112
Welborn, M., Kubicki, S. L., Garg, N., & Patel, A. B. (2020). Twelve cases of acneiform eruptions while on anti-CTLA4 therapy. Supportive Care in Cancer, 28(6), 2499–2502.
doi: 10.1007/s00520-020-05381-5
Kubicki, S. L., Welborn, M. E., Garg, N., Aung, P. P., & Patel, A. B. (2018). Granulomatous dermatitis associated with ipilimumab therapy (Ipilimumab associated granulomatous dermatitis). Journal of Cutaneous Pathology, 45(8), 636–638.
doi: 10.1111/cup.13267
Welborn, M. E., Kubicki, S. L., & Patel, A. B. (2018). Pyoderma Gangrenosum following initiation of immune checkpoint inhibitor therapy. Journal of Immunotherapy and Precision Oncology, 1(2), 82–84.
doi: 10.4103/JIPO.JIPO_11_18
Minkis, K., et al. (2013). The risk of rash associated with ipilimumab in patients with cancer: A systematic review of the literature and meta-analysis. Journal of the American Academy of Dermatology, 69(3), e121–e128.
doi: 10.1016/j.jaad.2012.12.963
Ohtsuka, M., Miura, T., Mori, T., Ishikawa, M., & Yamamoto, T. (2015). Occurrence of psoriasiform eruption during nivolumab therapy for primary oral mucosal melanoma. JAMA Dermatology, 151(7), 797–799.
doi: 10.1001/jamadermatol.2015.0249
Totonchy, M. B., Ezaldein, H. H., Ko, C. J., & Choi, J. N. (2016). Inverse psoriasiform eruption during pembrolizumab therapy for metastatic melanoma. JAMA Dermatology, 152(5), 590–592.
doi: 10.1001/jamadermatol.2015.5210
Schaberg, K. B., Novoa, R. A., Wakelee, H. A., Kim, J., Cheung, C., Srinivas, S., & Kwong, B. Y. (2016). Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy. Journal of Cutaneous Pathology, 43(4), 339–346.
doi: 10.1111/cup.12666
Jour, G., Glitza, I. C., Ellis, R. M., et al. (2016). Autoimmune dermatologic toxicities from immune check point blockade with anti-PD-1 antibody therapy: A report on bullous skin eruptions. Journal of Cutaneous Pathology, 43(8), 688–696.
doi: 10.1111/cup.12717
Naidoo, J., Schindler, K., Querfeld, C., et al. (2016). Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1. Cancer Immunology Research, 4(5), 383–389.
doi: 10.1158/2326-6066.CIR-15-0123
Freites-martinez, A., Kwong, B. Y., Rieger, K. E., Coit, D. G., Colevas, A. D., & Lacouture, M. E. (2017). Eruptive keratoacanthomas associated with pembrolizumab therapy. JAMA Dermatology, 153(7), 694–697.
doi: 10.1001/jamadermatol.2017.0989
Johnson, D., Patel, A. B., Uemura, M. I., et al. (2019). IL17A blockade successfully treated psoriasiform dermatologic toxicity from immunotherapy. Cancer Immunology Research, 7(6), 860–865.
doi: 10.1158/2326-6066.CIR-18-0682
Sowerby, L., Dewan, A. K., Granter, S., Gandhi, L., & Leboeuf, N. R. (2017). Rituximab treatment of nivolumab-induced bullous pemphigoid. JAMA Dermatology, 153(6), 603–605.
doi: 10.1001/jamadermatol.2017.0091
Lonowski, S., Sachsman, S., Patel, N., Truong, A., & Holland, V. (2020). Increasing evidence for omalizumab in the treatment of bullous pemphigoid. JAAD Case Reports, 6(3), 228–233.
doi: 10.1016/j.jdcr.2020.01.002
Kaye, A., Gordon, S. C., Deverapalli, S. C., Her, M. J., & Rosmarin, D. (2018). Dupilumab for the treatment of recalcitrant bullous pemphigoid. JAMA Dermatology, 154(10), 1225–1226.
doi: 10.1001/jamadermatol.2018.2526
Bezinelli, L. M., Eduardo, F. P., Migliorati, C. A., et al. (2019). A severe, refractory case of mucous membrane pemphigoid after treatment with pembrolizumab: Brief communication. Journal of Immunotherapy, 42, 359–362.
doi: 10.1097/CJI.0000000000000280
Common Terminology Criteria for Adverse Events (CTCAE) v4.0. (2008). http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm . Accessed 26 July 2016.
Brahmer, J. R., Lacchetti, C., Schneider, B. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., et al. (2018). Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 36(17), 1714–1768. https://doi.org/10.1200/JCO.2017.77.6385
doi: 10.1200/JCO.2017.77.6385
pubmed: 29442540
Hua, C., Boussemart, L., Mateus, C., et al. (2016). Association of vitiligo with tumor response in patients with meta-static melanoma treated with pembrolizumab. JAMA Dermatology, 152(1), 45–51.
doi: 10.1001/jamadermatol.2015.2707
Freeman-Keller, M., Kim, Y., Cronin, H., Richards, A., Gibney, G., & Weber, J. S. (2016). Nivolumab in resected and unresectable metastatic melanoma: Characteristics of immune-related adverse events and association with outcomes. Clinical Cancer Research, 22(4), 886–894.
doi: 10.1158/1078-0432.CCR-15-1136